AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25803245 — intervention group
Group type: COMPARATOR
Intervention: No intra‐articular injection (control group: CG)
Number of subjects: 40
Study 23769553 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimicifuga foetida extract (group A, n = 32)
Number of subjects: 96
Study 23769553 — intervention group
Group type: COMPARATOR
Intervention: Estradiol valerate and progesterone capsule (group B, n = 32)
Number of subjects: 96
Study 23769553 — intervention group
Group type: COMPARATOR
Intervention: Estradiol valerate and medroxyprogesterone acetate (group C, n = 32)
Number of subjects: 96
Study 21920203 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibial and common fibular nerve block using percutaneous nerve stimulator with 10 mL of levobupivacaine injected at each nerve site.
Number of subjects: 28
Study 21920203 — intervention group
Group type: EXPERIMENTAL
Intervention: Localization of tibial nerve using percutaneous stimulator.
Number of subjects: 28
Study 21920203 — intervention group
Group type: EXPERIMENTAL
Intervention: Localization of common fibular nerve using percutaneous stimulator.
Number of subjects: 28
Study 21920203 — intervention group
Group type: EXPERIMENTAL
Intervention: Localization of tibial nerve using nerve stimulator.
Number of subjects: 28
Study 21920203 — intervention group
Group type: EXPERIMENTAL
Intervention: Localization of common fibular nerve using nerve stimulator.
Number of subjects: 28
Study 21920203 — intervention group
Group type: EXPERIMENTAL
Intervention: Depth of needle insertion into tibial nerve.
Number of subjects: 28
Study 18218084 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-option decision aid (FOBT, sigmoidoscopy, combination of FOBT and sigmoidoscopy, colonoscopy, barium enema)
Number of subjects: 62
Study 18218084 — intervention group
Group type: COMPARATOR
Intervention: 2-option decision aid (FOBT and colonoscopy)
Number of subjects: 62
Study 16524668 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 200
Study 16524668 — intervention group
Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 200
Study 14650363 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitostanol
Number of subjects: 10
Study 14650363 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitostanol acetate
Number of subjects: 10
Study 14650363 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitostanol oleate
Number of subjects: 10
Study 14650363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10981219 — intervention group
Group type: EXPERIMENTAL
Intervention: Di-Te-Ki-Pol vaccine 'SSI'
Number of subjects: 270
Study 10981219 — intervention group
Group type: COMPARATOR
Intervention: DT-IPV plus wholecell pertussis vaccine
Number of subjects: 270
Study 8626963 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal oxygen therapy
Number of subjects: 22
Study 8626963 — intervention group
Group type: COMPARATOR
Intervention: Room air (control)
Number of subjects: 22
Study 1460749 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40
Study 1460749 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 40
Study 1460749 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline IOP before induction)
Number of subjects: 40
Study 29222892 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplements (Peptamen)
Number of subjects: 127
Study 29222892 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 127
Study 27067894 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise for 24 weeks
Number of subjects: 135
Study 27067894 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk walking for 24 weeks
Number of subjects: 135
Study 27067894 — intervention group
Group type: COMPARATOR
Intervention: Usual physical activity control for 24 weeks
Number of subjects: 135
Study 25098260 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGB)
Number of subjects: 60
Study 25098260 — intervention group
Group type: COMPARATOR
Intervention: Periocline
Number of subjects: 60
Study 25098260 — intervention group
Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 60
Study 22811009 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib plus Bevacizumab (1.3 mg/m² on days 1, 4, 8, and 11 of each 21-day cycle; Bevacizumab 15 mg/kg on day 1 of each cycle)
Number of subjects: 102
Study 22811009 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib monotherapy (1.3 mg/m² on days 1, 4, 8, and 11 of each 21-day cycle)
Number of subjects: 102
Study 22811009 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib plus Bevacizumab
Number of subjects: 102
Study 22811009 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib monotherapy
Number of subjects: 102
Study 19811937 — intervention group
Group type: EXPERIMENTAL
Intervention: Tender point examination (more than 8 TPs)
Number of subjects: 326
Study 19811937 — intervention group
Group type: EXPERIMENTAL
Intervention: Tender point examination (all patients included)
Number of subjects: 326
Study 19811937 — intervention group
Group type: EXPERIMENTAL
Intervention: Tender point examination (less than 6 TPs)
Number of subjects: 326
Study 18165579 — intervention group
Group type: EXPERIMENTAL
Intervention: Video‐before‐interview (Group 2)
Number of subjects: 209
Study 18165579 — intervention group
Group type: COMPARATOR
Intervention: No‐video (Group 1)
Number of subjects: 209
Study 18165579 — intervention group
Group type: EXPERIMENTAL
Intervention: Video‐after‐interview (Group 3)
Number of subjects: 209
Study 18165579 — intervention group
Group type: EXPERIMENTAL
Intervention: Video groups (Group 2 and Group 3)
Number of subjects: 209
Study 16539916 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol and terbutaline doses delivered via MDI with spacer (half the child's weight)
Number of subjects: 324
Study 16539916 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol and terbutaline doses delivered via MDI with spacer (one-third of the child's weight)
Number of subjects: 324
Study 12562445 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole, 20 mg once daily
Number of subjects: 1391
Study 12562445 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole, 15 mg once daily
Number of subjects: 1391
Study 11908405 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.3% hydrogen peroxide tooth-bleaching gel, used twice daily for 2 weeks
Number of subjects: 66
Study 11908405 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 66
Study 11908405 — intervention group
Group type: COMPARATOR
Intervention: Comparison between peroxide gel and placebo
Number of subjects: 66
Study 9291759 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia with propofol
Number of subjects: 112
Study 9291759 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol induction followed by inhalational anaesthesia with nitrous oxide and isoflurane
Number of subjects: 112
Study 9291759 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone induction followed by inhalational anaesthesia with nitrous oxide and isoflurane
Number of subjects: 112
Study 9291759 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 112
Study 8296377 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether (5 days intramuscular regimen)
Number of subjects: 54
Study 8296377 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 54
Study 3520308 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (up to 0.25 mg/kg/day)
Number of subjects: 27
Study 3520308 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 27
Study 30218837 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Consultation
Number of subjects: 188
Study 30218837 — intervention group
Group type: COMPARATOR
Intervention: No Consultation
Number of subjects: 188
Study 30218837 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation Including Audio Review
Number of subjects: 188
Study 26872109 — intervention group
Group type: EXPERIMENTAL
Intervention: peg‐IFN/RBV plus ezetimibe for 12 weeks followed by peg‐IFN/RBV for 12 weeks
Number of subjects: 144
Study 26872109 — intervention group
Group type: COMPARATOR
Intervention: peg‐IFN/RBV
Number of subjects: 144
Study 26872109 — intervention group
Group type: EXPERIMENTAL
Intervention: peg‐IFN/RBV plus ezetimibe
Number of subjects: 144
Study 23294347 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal goals activated (psychologically distant to psychologically close)
Number of subjects: 0
Study 23294347 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no goal activated)
Number of subjects: 0
Study 23430885 — intervention group
Group type: EXPERIMENTAL
Intervention: Counting gram protein exchanges (1g=50‐mg Phenylalanine)
Number of subjects: 26
Study 23430885 — intervention group
Group type: COMPARATOR
Intervention: Counting Phe unit exchanges (1unit=15‐mg Phenylalanine)
Number of subjects: 26
Study 23430885 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated diet chart allowing foods containing less than 50mg Phe per serve to be considered 'free'
Number of subjects: 26
Study 20098447 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of gestational diabetes mellitus
Number of subjects: 0
Study 19142004 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziziphus jujuba extract
Number of subjects: 37
Study 19142004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 16310129 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination in ninth graders with the law
Number of subjects: 75
Study 16310129 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccination in twelfth graders without the law
Number of subjects: 75
Study 16310129 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR and Td vaccination rates in both grades
Number of subjects: 75
Study 12904517 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (conjugated equine estrogens 0.625 mg/day plus medroxyprogesterone acetate 2.5 mg/day)
Number of subjects: 16608
Study 12904517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16608
Study 10863422 — intervention group
Group type: EXPERIMENTAL
Intervention: ChemFlex
Number of subjects: 92
Study 10863422 — intervention group
Group type: COMPARATOR
Intervention: Fuji IX GP
Number of subjects: 92
Study 8983284 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 5 mg/m2
Number of subjects: 187
Study 8983284 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 10 mg/m2
Number of subjects: 187
Study 8983284 — intervention group
Group type: COMPARATOR
Intervention: Both treatment arms (5 mg/m2 and 10 mg/m2)
Number of subjects: 187
Study 1751459 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of gentamicin at the end of the cataract procedure (Group G)
Number of subjects: 75
Study 1751459 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of gentamicin and a cellulose wick drain (Group GW)
Number of subjects: 75
Study 1751459 — intervention group
Group type: COMPARATOR
Intervention: Cellulose wick drain without gentamicin (Group W)
Number of subjects: 75
Study 7064901 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian meal with high content of ascorbic acid
Number of subjects: 187
Study 7064901 — intervention group
Group type: COMPARATOR
Intervention: Meals containing meat and fish
Number of subjects: 187
Study 7064901 — intervention group
Group type: COMPARATOR
Intervention: Reference dose of inorganic iron (3 mg)
Number of subjects: 187
Study 31087065 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication reconciliation at discharge by a clinical pharmacist, a prescription check for formal flaws, interactions and missing therapy durations.
Number of subjects: 152
Study 31087065 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard discharge process).
Number of subjects: 152
Study 31087065 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group.
Number of subjects: 152
Study 28340157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical lateral glide (CLG) treatment
Number of subjects: 58
Study 28340157 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - waiting list for treatment
Number of subjects: 58
Study 25775376 — intervention group
Group type: EXPERIMENTAL
Intervention: Nametag positioned on the right chest side
Number of subjects: 100
Study 25775376 — intervention group
Group type: COMPARATOR
Intervention: Nametag positioned on the left chest side
Number of subjects: 100
Study 23677817 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (INCB018424 Phosphate)
Number of subjects: 272
Study 21482587 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (PORT)
Number of subjects: 221
Study 19934707 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-extremity musculotendinous surgery
Number of subjects: 75
Study 19934707 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical cohort (control)
Number of subjects: 75
Study 17890993 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-page HIPAA authorization form (HAF)
Number of subjects: 6939
Study 17890993 — intervention group
Group type: COMPARATOR
Intervention: No HIPAA authorization form (No HAF)
Number of subjects: 6939
Study 12690582 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness intervention program (lifestyle‐change classes for 8 weeks, followed by telephone follow‐up for 3 months)
Number of subjects: 113
Study 12690582 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness intervention program
Number of subjects: 113
Study 10920403 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg plus naproxen sodium 550 mg
Number of subjects: 67
Study 10920403 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan 100 mg plus placebo
Number of subjects: 67
Study 8959522 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy with lansoprazole (30 mg o.d.) for 8 weeks plus clarithromycin (200 mg b.i.d.) or amoxicillin (250 mg q.i.d.) for 2 weeks
Number of subjects: 55
Study 8959522 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with lansoprazole (30 mg o.d.) and ecabet sodium (1.0 g b.i.d.) for 8 weeks plus clarithromycin (200 mg b.i.d.) or amoxicillin (250 mg q.i.d.) for 2 weeks
Number of subjects: 55
Study 1413183 — intervention group
Group type: EXPERIMENTAL
Intervention: Venoruton (300 mg x 3)
Number of subjects: 43
Study 1413183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 3549312 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100-200 mg daily)
Number of subjects: 32
Study 3549312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 30208960 — intervention group
Group type: EXPERIMENTAL
Intervention: SAM® Medical Junctional Tourniquet (SJT)
Number of subjects: 227
Study 30208960 — intervention group
Group type: EXPERIMENTAL
Intervention: Junctional Emergency Treatment Tool (JETT)
Number of subjects: 227
Study 30208960 — intervention group
Group type: COMPARATOR
Intervention: JETT
Number of subjects: 227
Study 30208960 — intervention group
Group type: EXPERIMENTAL
Intervention: SJT
Number of subjects: 227
Study 26671007 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT), 24 IU
Number of subjects: 32
Study 26671007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 25270192 — intervention group
Group type: EXPERIMENTAL
Intervention: PA-PALs with +1.5 D addition
Number of subjects: 197
Study 25270192 — intervention group
Group type: COMPARATOR
Intervention: Single vision lenses (SVLs)
Number of subjects: 197
Study 25270192 — intervention group
Group type: EXPERIMENTAL
Intervention: PA-PALs with +1.0 D addition
Number of subjects: 197
Study 22500855 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmesocolic laparoscopic pyeloplasty (TM)
Number of subjects: 64
Study 22500855 — intervention group
Group type: COMPARATOR
Intervention: Colon-reflecting laparoscopic pyeloplasty (CR)
Number of subjects: 64
Study 20592724 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg
Number of subjects: 10
Study 20592724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 17572521 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl chloride spray (EC)
Number of subjects: 55
Study 17572521 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthetic Ametop (TA)
Number of subjects: 55
Study 17572521 — intervention group
Group type: COMPARATOR
Intervention: No analgesia (NO)
Number of subjects: 55
Study 15661445 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dextromethorphan (DM) 0.5 mg/kg
Number of subjects: 24
Study 15661445 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 24
Study 12142863 — intervention group
Group type: EXPERIMENTAL
Intervention: Adderall (standard release)
Number of subjects: 6
Study 10567867 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of recombinant tissue plasminogen activator (rtPA) and intravenous heparinization (n = 23)
Number of subjects: 58
Study 10567867 — intervention group
Group type: EXPERIMENTAL
Intervention: early-phase hemodilution therapy (n = 22)
Number of subjects: 58
Study 10567867 — intervention group
Group type: COMPARATOR
Intervention: late-phase hemodilution therapy (n = 13)
Number of subjects: 58
Study 8724107 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp(a) ≥ 20 mg/dl
Number of subjects: 369
Study 8724107 — intervention group
Group type: COMPARATOR
Intervention: Lp(a) < 20 mg/dl
Number of subjects: 369
Study 2035283 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.5 g fish oil daily
Number of subjects: 0
Study 2035283 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25 g fish oil daily
Number of subjects: 0
Study 2035283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6786855 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone (50 mg Biogastron duodenal three times daily)
Number of subjects: 81
Study 6786855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 31565784 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated storyline training materials
Number of subjects: 300
Study 31565784 — intervention group
Group type: COMPARATOR
Intervention: Plain text training materials
Number of subjects: 300
Study 31621546 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0
Study 31621546 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 28143413 — intervention group
Group type: EXPERIMENTAL
Intervention: EMPOWER brochure intervention
Number of subjects: 303
Study 24913197 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 150 mg/d
Number of subjects: 370
Study 24913197 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg/d
Number of subjects: 370
Study 24887922 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal muscle flap and intracostal sutures in the study group (n=23)
Number of subjects: 48
Study 24887922 — intervention group
Group type: COMPARATOR
Intervention: Conventional closure with pericostal sutures in the conventional group (n=25)
Number of subjects: 48
Study 22075648 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic-release oral system (OROS) methylphenidate
Number of subjects: 30
Study 22075648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19433778 — intervention group
Group type: EXPERIMENTAL
Intervention: ramipril (5 mg/d) at bedtime
Number of subjects: 115
Study 19433778 — intervention group
Group type: COMPARATOR
Intervention: ramipril (5 mg/d) on awakening
Number of subjects: 115
Study 17766632 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (1-day educational programme)
Number of subjects: 81
Study 17766632 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention, n = 24)
Number of subjects: 81
Study 15086937 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual psychotherapy (12-week course)
Number of subjects: 89
Study 15086937 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychotherapy (12-week course)
Number of subjects: 89
Study 15086937 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 89
Study 11222463 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 5 mg/m2
Number of subjects: 47
Study 11222463 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 12 mg/m2
Number of subjects: 47
Study 11222463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 9587009 — intervention group
Group type: EXPERIMENTAL
Intervention: LAM intervention
Number of subjects: 698
Study 7912097 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (1000 mg daily in two divided doses)
Number of subjects: 143
Study 7912097 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 143
Study 7912097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 2680274 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce calorie intake
Number of subjects: 841
Study 2680274 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce sodium intake
Number of subjects: 841
Study 2680274 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce sodium and calorie intake
Number of subjects: 841
Study 2680274 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce sodium and increase potassium intake
Number of subjects: 841
Study 2680274 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary counseling)
Number of subjects: 841
Study 370019 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole alone
Number of subjects: 0
Study 370019 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole plus trimethoprim
Number of subjects: 0
Study 30983506 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-day fasting (ADF)
Number of subjects: 100
Study 30983506 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR)
Number of subjects: 100
Study 30983506 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study 28187125 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (150 minutes per week for 26 weeks)
Number of subjects: 76
Study 28187125 — intervention group
Group type: COMPARATOR
Intervention: Non-aerobic stretching and toning (control group)
Number of subjects: 76